Please login to the form below

The role of medical affairs in positive and appropriate engagement with patient advocacy groups

Written by Gavin Jones, Dr Alexandra Safronova & Professor Peter Rutherford, OPEN Health

Following a series of workshops at a recent Medical Affairs Professionals Society (MAPS) Congress in Amsterdam, workshop leaders Gavin Jones, Dr Alexandra Safronova and Professor Peter Rutherford share their lessons learnt on how medical affairs departments within pharmaceutical companies can help create better partnerships with patient advocacy groups

Pink divider

Patient advocacy groups continue to mobilise and play an increasingly important role in delivering advice and support helping to get treatments to those most in need by Influencing many elements of drug development and patient access processes. This is very much the case in rare disease where groups give critical support to patients and those close to them through influential programmes delivered  with passion and dogged persistence.

Biopharma recognises the importance of positive engagement and partnership with patient groups. Gaining a far greater understanding of the patient journey helps to translate innovations into actual benefits for patients and caregivers in improved clinical outcomes and patient experience.

A question remains around how, and which part of a biopharma organisation should be involved in building patient group relationships. Many organisations invest in patient advocacy leads to support engagement, but they are often brought in to support dialogue as new treatment is becoming available.  As   patient  groups  are  rightly  getting involved in activities much earlier in the drug development process who should lead engagement at this stage and support over the longer term?

This was a question that was posed at workshops during the recent Medical Affairs Professionals (MAPS) meeting in Europe. MAPS is an organisation that supports the sharing of best practice amongst leaders in this key function of pharmaceutical companies. So, who are medical affairs and what is their role?

Read the full article here: https://bit.ly/37IYg5

Pink divider

Get in touch

For more information on rare disease contact:

Gavin Jones, Director of Rare Disease, OPEN Health

Gavinjones@openhealthgroup.com

30th January 2020

Share

Company Details

OPEN Health

+44 1628 481112

Contact Website

Address:
The Weighbridge
Brewery Courtyard
High Street
Marlow
Buckinghamshire
SL7 2FF
United Kingdom

Latest content on this profile

OPEN Health Appoints David P. King as Non-Executive Chairman and Paul Carter as Independent Board Member
OPEN Health has announced additions to its board of directors, appointing David P. King as non-executive Chairman and Paul Carter as an independent board member.
OPEN Health
Steve Chick joins OPEN Health as Chief Growth Officer for Evidence & Access
OPEN Health is pleased to announce the appointment of Stephen J. Chick as Chief Growth Officer for OPEN Health Evidence & Access.
OPEN Health
OPEN Health to acquire leading US medical communications platform The CM Group from NaviMed Capital
OPEN Health, a pre-eminent global provider of scientific communications and market access services, announced that it signed a binding agreement to acquire The CM Group, a leading US domestic medical communications platform from NaviMed Capital (“NaviMed”).
OPEN Health
How digital health is changing the relationship between patients and health providers | OPEN Health
The pandemic has forced pharmaceutical industry to look at digital in a new way - and it’s driving better health outcomes
OPEN Health
David Thompson joins OPEN Health as Chief Executive Officer for Evidence & Access
David Thompson joins OPEN Health as Chief Executive Officer for Evidence & Access
OPEN Health
OPEN Health Appoints Chief Medical Officer Annemarie Clegg, MD, and Chief Commercial Officer Jennifer Chilver
OPEN Health Appoints Chief Medical Officer Annemarie Clegg, MD, and Chief Commercial Officer Jennifer Chilver
OPEN Health